Tilmacoxib (JTE-522) is a highly selective, time-dependent, and irreversible COX-2 inhibitor with potential anti-inflammatory and chemopreventive applications; it significantly suppresses the formation of colonic aberrant crypt foci (ACF), a marker of colon carcinogenesis, in a rat model; it also inhibits lipopolysaccharide-induced prostaglandin E2 production in human peripheral blood mononuclear cells and demonstrates anti-proliferative effects on gastric epithelial cells via a PGE2-independent pathway.